Development and validation of a casemix classification to predict costs of specialist palliative care provision across inpatient hospice, hospital and community settings in the UK: a study protocol by Guo, Ping. et al.
1Guo P, et al. BMJ Open 2018;8:e020071. doi:10.1136/bmjopen-2017-020071
Open Access 
Development and validation of a 
casemix classification to predict costs of 
specialist palliative care provision 
across inpatient hospice, hospital and 
community settings in the UK: a 
study protocol
Ping Guo,1 Mendwas Dzingina,1 Alice M Firth,1 Joanna M Davies,1 Abdel Douiri,2 
Suzanne M O'Brien,1 Cathryn Pinto,1 Sophie Pask,1 Irene J Higginson,1 
Kathy Eagar,3 Fliss E M Murtagh4
To cite: Guo P, Dzingina M, 
Firth AM, et al.  Development 
and validation of a casemix 
classification to predict costs 
of specialist palliative care 
provision across inpatient 
hospice, hospital and 
community settings in the UK: 
a study protocol. BMJ Open 
2018;8:e020071. doi:10.1136/
bmjopen-2017-020071
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
020071).
Received 12 October 2017
Revised 6 February 2018
Accepted 8 February 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Ping Guo;  
 ping. guo@ kcl. ac. uk
Protocol
AbstrACt
Introduction Provision of palliative care is inequitable 
with wide variations across conditions and settings in the 
UK. Lack of a standard way to classify by case complexity 
is one of the principle obstacles to addressing this. We 
aim to develop and validate a casemix classification to 
support the prediction of costs of specialist palliative care 
provision.
Methods and analysis  Phase I: A cohort study to 
determine the variables and potential classes to be 
included in a casemix classification. Data are collected 
from clinicians in palliative care services across inpatient 
hospice, hospital and community settings on: patient 
demographics, potential complexity/casemix criteria and 
patient-level resource use. Cost predictors are derived 
using multivariate regression and then incorporated into 
a classification using classification and regression trees. 
Internal validation will be conducted by bootstrapping 
to quantify any optimism in the predictive performance 
(calibration and discrimination) of the developed 
classification. Phase II: A mixed-methods cohort study 
across settings for external validation of the classification 
developed in phase I. Patient and family caregiver data 
will be collected longitudinally on demographics, potential 
complexity/casemix criteria and patient-level resource use. 
This will be triangulated with data collected from clinicians 
on potential complexity/casemix criteria and patient-level 
resource use, and with qualitative interviews with patients 
and caregivers about care provision across difference 
settings. The classification will be refined on the basis of 
its performance in the validation data set.
Ethics and dissemination The study has been approved 
by the National Health Service Health Research Authority 
Research Ethics Committee. The results are expected to 
be disseminated in 2018 through papers for publication in 
major palliative care journals; policy briefs for clinicians, 
commissioning leads and policy makers; and lay 
summaries for patients and public.
trial registration number ISRCTN90752212. 
IntroduCtIon 
People with advanced and incurable illness 
often suffer complex and multiple symptoms 
and psychosocial concerns because of their 
illness or impending death.1 2 Their families 
may provide day-to-day care, as well as be 
affected by their own anxieties, concerns and 
potential losses. These bring increased need 
for health and social care, with need being 
defined as ‘the ability to benefit from health 
or social care interventions’.3 Palliative care 
has developed to meet the needs of these 
patients and families, which addresses phys-
ical/psychological symptoms and provides 
social, practical and spiritual support. The 
UK ranks first in the 2015 Quality of Death 
strengths and limitations of this study
 ► This is the first study in the UK to determine the vari-
ables and potential classes to be included in a case-
mix classification, which predicts costs of specialist 
palliative care provision across inpatient hospice, 
hospital and community settings.
 ► Transparent Reporting of a multivariable prediction 
model for Individual Prognosis Or Diagnosis is used 
to guide the reporting of this study.
 ► The newly developed casemix classification in 
phase I will be externally validated by using a differ-
ent data set in phase II.
 ► This study also promotes the implementation of out-
come measures in palliative care into routine clinical 
practice across different settings of care.
 ► This is a UK-focused study so the casemix classifi-
cation may not be directly applied to palliative care 
in other countries without further investigation and 
refinement.
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Index—a measure of the quality of dying in 80 countries,4 
and the hospice movement in the UK has provided a 
model of good palliative care for those in need.
However, marked inequities exist in provision of palli-
ative care across England. Older people and those with 
non-cancer diagnoses are less likely to access specialist 
palliative care.5 6 There are also major geographical vari-
ations, ranging from £186 to £6213 per person across 
different primary care trusts in 2010,7 8 often resulting in a 
poor match between individual needs, resources provided 
to meet those needs and health outcomes achieved. With 
an ageing population and increasing rates of chronic 
diseases, the growing healthcare burden is overwhelm-
ingly challenging in terms of health resource allocation 
around the UK.9 With recognition of the constraints on 
resources, there is support for the systematic approach 
to mapping individual needs accurately and improving 
the quality and efficiency of palliative care. This has been 
endorsed as a high priority nationally.7
The Diagnosis-Related Group is a useful classifica-
tion of healthcare needs driven by the diagnosis but is 
inappropriate for palliative care, because palliative care 
needs are not driven by the diagnosis but by factors such 
as functional status and symptoms. Palliative care needs 
a consistent method of classifying types of patients with 
complexity of needs, treatment and costs, using casemix 
criteria.10–12 It is necessary to identify those with more 
complex palliative needs, requiring more resources. An 
Australian casemix classification for palliative care was 
developed in 1997, empirically tested and progressively 
refined over time.13–15 The Australian casemix classifica-
tion consists of classes defined by five criteria including 
phase of illness, problem severity, functional status and 
dependency, age and model of care, as most strongly 
predictive of resource use.16 Full class definition and 
categorisation are available at http://www. pcoc. org. au/. 
Its implementation proved the possibility of consistently 
and routinely collecting data in practice in Australia.16 
However, due to variations in outcome measures collected 
and palliative care provided between countries, it is 
unclear whether any existing palliative care classification 
can be easily applied to the UK to address unmet needs 
and resolve the inequity.
This study is part of a 5-year National Institute for Health 
Research-funded C-CHANGE programme (RP-PG-1210–
12015). It aims to develop and validate a casemix classi-
fication for palliative care in the UK. Specific objectives 
are:
 ► To determine the cost predictors of specialist pallia-
tive care, adjusting for important confounding factors 
including unmet needs.
 ► To develop and validate a casemix classification for 
specialist palliative care.
MEthods And AnAlysIs
The Transparent Reporting of a multivariable prediction 
model for Individual Prognosis Or Diagnosis statement17 
is used to guide the reporting of this study protocol.
study design and source of data
This study consists of two phases: development phase 
(phase I) and validation phase (phase II). In the analysis 
part of phase I, we will identify variables that predict costs 
to be included in casemix classification through a cohort 
study with only clinician data, and develop potential 
casemix classes for palliative care which will be tested in 
individual episodes of care (internal validation). In phase 
II, we will prospectively validate these potential classes in 
a new cohort study with patient, caregiver and clinician 
data, and include qualitative interviews to ensure it works 
during care transitions and longitudinally over the course 
of illness (external validation).
Phase I: development phase
This is a cohort study to determine the variables and 
potential classes to be included in a casemix classifica-
tion, based on individual episodes of care across inpa-
tient (hospice and hospital) and community settings. An 
‘episode of care’ starts when a patient is admitted to inpa-
tient services or begins to receive specialist palliative care 
from a community-based or outpatient service, and ends 
when a patient is discharged from that service or dies. 
The median duration of an episode of care is expected to 
be under 14 days in inpatient and at a median of 72 days 
in community settings.18
Phase I was conducted between 31 July 2015 and 30 
September 2016 and follow-up ended on 30 November 
2016. Data were collected from clinicians through surveys, 
including demographic/clinical data, episode start/
end data, patient attributes that predict palliative care 
resource consumption (eg, phase of illness, functional 
status and problem severity as identified in the Austra-
lian casemix classification study13 14 16), plus information 
on patient-level resource use (staff activity and clinical 
services) in specialist palliative care settings.
Phase II: validation phase
This phase is a mixed-methods cohort study with a concur-
rent nested design:19
 ► Quantitative main component—prospectively collect 
data from patients, caregivers and clinicians on pallia-
tive care needs, concerns, outcomes and resource use.
 ► Qualitative nested component—longitudinal inter-
views with a subsample of participants to understand 
care provision in each setting and transitions between 
settings.
Phase II will be conducted between 1 November 2016 
and 30 April 2018, with follow-up ending on 31 May 2018. 
The same variables and measurements as phase I will be 
collected from clinicians. Additionally, patient/caregiver 
participants will provide data on symptoms/concerns, 
experience of care and their use of services, and will be 
followed through all episodes of care from recruitment to 
death or the end of this study. A post bereavement survey 
will be conducted with caregivers where appropriate to 
identify symptoms/concerns immediately prior to death 
and support needs after death.
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Participants
Phase I: development phase
All adults (≥18 years) receiving specialist palliative care 
newly admitted in 10 participating sites during the study 
period (two sites providing hospital advisory services, one 
providing community-based service only, six providing 
hospice inpatient and community-based services, one 
providing hospital advisory and community-based 
services) were included, regardless of primary diagnosis. 
We selected these sites with the aim of ensuring a repre-
sentative sample in terms of population demographics 
(age distribution, ethnicity, socioeconomic status and 
rural/urban composition). Written informed consent 
was taken by a qualified member of the research or clin-
ical team. This phase included individuals with limited, 
fluctuating, diminishing or lack of capacity, vital to 
ensure that any casemix classification is applicable to 
all palliative patients, not just those able to consent. It is 
recognised that a high proportion of those have impaired 
capacity, and these patients may need palliative care and 
resources most.20–23 Therefore, if the clinician assessed 
that the patient did not currently have the capacity to give 
consent, assent was sought from an accompanying family 
member, or failing that, a staff member to whom the 
patient was known. Where a formally appointed power of 
attorney existed, this took precedence.
Phase II: validation phase
All adults (≥18 years) receiving specialist palliative care 
newly admitted from 14 sites during the study period 
(participating sites in phase I, but extending to four addi-
tional sites to increase recruitment) will be eligible, regard-
less of primary diagnosis. Additional sites were accepted 
if they could contribute to maintaining or extending 
representativeness in terms of population demographics 
(age distribution, ethnicity, socioeconomic status and 
rural/urban composition). Written informed consent will 
be sought from eligible patients (and their family care-
givers) at the outset, including advance consent for study 
follow-up if capacity is lost. This study is of minimal risk 
with participants not exposed to undue harm.24
For both phase I and II, a list of study sites can be 
obtained via https://www. kcl. ac. uk/ nursing/ depart-
ments/ cicelysaunders/ research/ studies/ c- change/ c- 
change. aspx.
Since transition of care is important for casemix, patient 
participants who transfer between settings (and caregiver 
participants) will be followed up. We will verbally confirm 
continuing consent with each participant when making 
such contact. If capacity of patient participants is lost, we 
will seek advice from a personal consultee on whether the 
patient should remain in the study to verify no change of 
decisions has been expressed by the patient prior to loss of 
capacity. On recruitment, participants will be asked if they 
are willing to be interviewed at a later stage. To capture 
variation in age, gender, diagnosis and geographical loca-
tion, we will purposively select 20–25 patients and family 
caregivers with at least two transitions of care for face-to-
face interviews. Each semistructured interview will last 
40 min, but will be guided by each participant. In order 
to provide information on how care transitions might be 
better negotiated to improve outcomes and experiences, 
the interviews will cover communication, coordination 
of care, information/support needs, discharge planning 
and experience of transitions.
outcome
The outcome is cost of specialist palliative care (including 
per diem cost, per phase cost, and total episode cost) 
captured by: (1) staff activity matrix in both the develop-
ment and validation phase, (2) the Palliative care Resource 
Use Score (PRUS) in both phases and (3) Palliative Client 
Services Receipt Inventory (Pall-CSRI) in validation phase 
only.
Staff activity
At every contact, nurses, doctors and allied health profes-
sionals will record the time spent on face-to-face and 
phone contacts, and patient-level administrative time per 
shift using the staff activity matrix paper version (table 1). 
Staff training and site feedback of activity data were 
conducted regularly to improve and optimise data quality.
Palliative care Resource Use Score
PRUS is a questionnaire specifically designed to capture 
palliative care resource use in a standardised way. It will 
be collected by the staff at change of ‘phase of illness’25 26 
and at the end of each episode by recording the following 
information for the phase which has ended:
 ► Level of professional input (eg, registered nurses, 
specialist palliative nursing staff, palliative doctors 
and social workers) and whether this met patient/
family needs.
 ► Level of ‘out-of-hours’ services by professional 
designation.
 ► Equipment, high-cost drugs, diagnostic tests and 
medical imaging. Within PRUS, the member of staff 
is asked to indicate whether or not equipment, high-
cost oral/transdermal medications, injectable medi-
cations/interventions and medical imaging or tests 
were received by the participant, from a list derived 
from prior work to identify these options.
Table 1 Staff activity matrix (each box is completed in units of 5 min, from 0 up to 120 min)
Staff time (mins) Patient Family/carer Professional (internal) Professional (external)
Face-to-face/phone time
Administrative time
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 ► Any unmet needs which provide insight into any 
gaps between needs and provision, as identified by 
a member of staff.27–29 When completing PRUS, the 
member of staff is asked to estimate retrospectively 
if there were any unmet needs (yes/no) in the care 
provided by healthcare assistants, registered nurses, 
palliative medicine doctors and allied healthcare 
professionals. This member of the staff is also asked 
whether there were any unmet needs in out-of-hours 
care, and whether the equipment provided met the 
patient’s needs. If there were unmet needs identified 
in any of these areas above, a free text field is provided 
to specify these unmet needs.
Palliative Client Services Receipt Inventory
The Pall-CSRI is a patient/caregiver completed inventory 
of palliative care services received, and adapted from those 
used with palliative care populations.30 It takes approx-
imately 20 min to complete and collect retrospective 
information about the use of health/social care services, 
medication, living situation, income, employment and 
benefits, plus informal care. The Pall-CSRI will be collected 
once every three months or at the end of each episode of 
care, whichever is earlier in the validation phase.
In the development phase, only direct care costs will be 
calculated but not productivity losses.31 Direct care cost 
refers to all costs due to resource use that are completely 
attributable to the use of a healthcare intervention or 
illness, which can be split into direct medical costs (the 
cost of a defined intervention and all follow-up costs for 
other medication and healthcare interventions in ambu-
latory, inpatient, nursing care, home or other relevant 
settings) and direct non-medical costs (eg, transportation 
costs and additional paid caregiver time).32 In the valida-
tion phase, we will use the same health services costing 
perspective as in the development phase, but informal 
care costs are also considered to be in-scope and will 
be analysed separately, hypothesising that informal care 
costs are (1) greater in those with unmet needs, and (2) 
greater in those with non-cancer conditions. The costs of 
each resource item will be calculated by combining the 
resource use data with appropriate unit cost obtained 
from recognised sources including the annual compen-
dium produced by the Personal Social Services Research 
Unit,33 prices on the National Health Service (NHS) 
supply chain website http://www. supplychain. nhs. uk, 
British national formulary34 and NHS reference costs.35 
The focus will be on staff time—the main resource in 
palliative care documented in a variety of settings and 
countries.36–38 We will attribute costs according to a stan-
dard costing methodology adopted from the current 
NHS costing principles.39
Predictors (casemix criteria)
Proposed cost predictors can be categorised into three 
groups: (1) predictors collected from clinicians, (2) 
predictors collected from patients/family caregivers and 
(3) model of care.
Predictors collected from clinicians
In both the development and validation phases, clinicians 
will record demographic, clinical and episode start adminis-
trative data. Episode end data will be collected at the end of 
each episode of care. Casemix data include phase of illness 
(stable, unstable, deteriorating, dying), functional status 
(measured by Australia-modified Karnofsky Performance 
Status (AKPS)), dependency (Modified Barthel Index), 
problem severity (Integrated Palliative care Outcome 
Scale—IPOS staff version) and caregiver needs (table 2). 
The measures are available directly from phase of illness 
(www. pcoc. org. au), AKPS,40 Modified Barthel Index41 
and IPOS (www. pos- pal. org), respectively. Phase of illness 
will be assessed daily for people receiving inpatient care 
and at each face-to-face contact basis for those receiving 
community-based care. Other variables including AKPS, 
Modified Barthel Index, IPOS staff (and caregiver needs 
when feasible) will be collected at the start of episode, end 
of episode and at change of phase of illness.
Predictors collected from patients and family caregivers
Variables (table 3) will be collected in the validation 
phase from patients/caregivers using face-to-face/
Table 2 Data from clinicians in both development phase 
and validation phase
Type of data Proposed cost predictors
Demographic data Age
Gender
Postcode
Ethnicity
Marital status
Living circumstances
Need for interpreter
Setting of care
Clinical data Primary diagnosis
Secondary diagnoses
Comorbidities
Episode start and end data Episode start date
Episode end date
Endpoint of episode 
(discharged or died).
Discharge destination, if 
discharged
Key casemix Phase of illness at start of 
episode
Functional status (AKPS)
Dependency (Modified 
Barthel Index)
Problem severity (IPOS staff 
version)
Family/caregiver needs
AKPS, Australia-modified Karnofsky Performance Status; IPOS, 
Integrated Palliative care Outcome Scale.
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telephone contacts and postal questionnaires according 
to their preferences. IPOS patient version and Distress 
Thermometer will be collected from patients at the start 
of episode, at change of phase of illness and at the end 
of episode. Views on Care and Short-Form Health Survey 
V.2.0 (SF-12v2) will be collected at the start and end of 
each episode of care. Selected questions capturing expe-
riences of integrated care42 will be collected at the end of 
episode only.
All caregiver- reported measures will be collected at the 
start of episode, at change of phase of illness and at the 
end of episode. Where phase length exceeds 4 weeks, data 
collected from patients (and caregivers) will be captured 
as a change of phase. If the patient is transferred to an 
out-of-scope inpatient setting, we will follow up with the 
patient when he or she gets home and retrospectively 
collect minimum information about this episode of care.
If the patient is deceased, data such as SF-12v2 and 
Pall-CSRI will be collected from the participating care-
giver three months after death by postal questionnaire, 
along with the bereavement support information and 
contacts. The time between death and the postal ques-
tionnaire may influence caregivers’ willingness to share 
their views; shorter periods possibly being too upsetting 
to contemplate involvement.43 There is mixed evidence of 
the best time to make contact with potential participants 
for follow-back surveys44 45 and 3–4 months post bereave-
ment is considered acceptable by bereaved families.30
Model of care
Models of care may be a stronger cost driver than patient-
level variables.13 14 16 Specialist palliative care services have 
various configurations of staff, interventions and other 
characteristics. Currently, there is no consistent way to 
define models of palliative care. A separate, parallel study 
will be conducted in which service-level data including 
the numbers, disciplines and grading of staff, the nature/
duration of their involvement and use of volunteers will 
be collected to comprehensively characterise different 
models of palliative care provision in the participating 
sites. With findings from this step, a new categorical 
variable will be created representing ‘model of care’ to be 
included in our analysis.
sample size
In the development phase, based on standard recommen-
dations for fitting multivariate models, a minimum of 
50+8×m (where m is the number of predictors) is required 
to test the hypothesis that the population multiple correla-
tion equals zero with a power of 80%, alpha=5% and a 
medium effect size for the regression analysis (R2=0.13).46 
We estimated a sample size of 450 episodes per setting 
(allowing for 25% incomplete episodes and up to 10% 
of complete episodes being cost outliers with unusually 
high or low costs). A total of 1350 patient episodes across 
settings is needed.
In the validation phase, again a minimum of 50+8×m 
(where m is the number of predictors) is required to 
test the hypothesis that the population multiple correla-
tion equals zero with a power of 80%, alpha=5% and a 
medium effect size for the regression analysis (R2=0.13).46 
In phase II, the number of predictors reflects the casemix 
variables, and needs to be clinically relevant47 to ensure 
a meaningful casemix classification. We expect the final 
casemix classification to contain 5–8 casemix variables, 
based on the Australian experience.13 We have estimated 
that data from 114 (50+(8×8)) episodes of care per setting 
(hospice, hospital, community) are needed. Assuming an 
average of three episodes per participant15 in this longi-
tudinal phase, this represents at least 38 participants per 
setting. Allowing for 50% attrition, we estimate needing 
a total of 228 participants, which will provide about 684 
patient episodes. The sample size will be recalculated 
and inflated using the design effect based on intraclass 
correlation which will be estimated through interim anal-
yses. A total of 300 participants across settings is needed, 
including extra 25% participants allowing for intraclass 
correlation.
Missing data and data handling
Data will be collected prospectively and recorded on an 
electronic database. Any data transferred from the sites 
to the central study database will be carried out under 
the NHS Code of Practice on Confidentiality. Data will 
be cleaned and cross-checked using a number of internal 
checks (automated data validation on entry, indepen-
dent cross-checking of a 5% sample of data from each 
site and range checking across all data types) to track 
errors and inconsistencies and amend where possible. 
Checked data will be transferred to statistical software 
(Stata SE V.12) for analysis. Missing value analysis will 
be used to quantify missing values and understand the 
reason for missing data: dropout of participants, errors 
in data entry and missing with no identifiable reasons. 
We will adopt multiple imputation technique based on 
Markov Chain Monte Carlo techniques if the percentage 
of observed missing values in independent variables 
exceeds 10% provided values are missing at random, 
and carry out sensitivity analysis for effects on casemix 
Table 3 Predictors collected from patients and family 
caregivers in validation phase only
Data collection from 
patients
Data collection from family 
caregivers
IPOS patient version Basic demographic 
information
Distress Thermometer Distress Thermometer
Views on Care Two caregiver questions
SF-12v2* Zarit six items
Patient experiences of 
integrated care
*The measure could be completed by a family caregiver if the 
patient is too unwell to complete.
SF -12v2, Short-Form Health Survey V.2.0. 
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classification, predictive validity and misclassification, 
where feasible.
statistical analysis methods
We will use descriptive statistics including frequencies, 
mean and SD, and median and interquartile ranges 
as appropriate to describe the sample characteristics 
and number and length of episodes of care. Trajectory 
of outcomes and costs will be described, comparing 
patterns in patients with cancer and without cancer, and 
contrasting those with no unmet needs and those with 
unmet needs. We will compare our data with existing 
phase and episode data from the Australian Palliative 
Care Outcome Collaboration.48 In the Australian classi-
fication, five casemix criteria (phase of illness, problem 
severity, functional status and dependency, age, model 
of care) were found to be most strongly predictive of 
resource use. If our analyses demonstrate the same five 
criteria as most predictive of resource use, the Australian 
classification or a refinement of it will be adopted. If there 
is disparity, then the data on individual casemix criteria 
will be used to develop a new casemix classification, using 
a recursive partitioning approach—specifically classifica-
tion and regression trees49 50compared with multivariable 
regression (figure 1).
Qualitative analysis methods
Audio-recordings will be transcribed verbatim and 
checked for accuracy and entered into NVivo V.10. Data 
will be independently coded and analysed by two members 
of the research team. We will adopt a similar approach to 
Pinnock,51 undertaking a thematic and narrative analysis 
of interviews, exploring how perspectives evolve over time, 
with detailed attention to patient and family perspectives 
on experience of care in each setting and transitions, 
including potential interventions (and hence cost levers 
or other triggers) to influence changes in settings of care.
Model development
The distribution of casemix criteria (cost predictors) in 
the participant population will be described based on 
phase of illness, functional status and problem severity, 
using parametric or non-parametric statistics, as appro-
priate. In order to reduce the number of cost predictors, 
Figure 1 Data analysis flowchart. CART, classification and regression trees.
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we will initially use univariate analysis to explore the 
association and strength of association between casemix 
criteria and cost of the episode of care (quantifying cost 
by per diem cost, per phase cost and total cost of episode). 
We will use generalised linear model (multivariate regres-
sion model) to select variables that will then be applied in 
a hierarchical manner to form a branching classification 
in which each cost driver is incorporated only once.
We will select variables according to how much of the 
predictive error (R2) each variable predicts and the related 
P value. After each bootstrap iteration, we will rank the 
variables according to these two criteria and remove the 
weakest (non-significant) predictor. Variables shown in 
tables 2 and 3 and the newly created categorical variable 
representing ‘model of care’ will be initially entered into 
the models and then non-significant predictors removed 
at each iteration using a Bootstrap subsampling strategy. 
We will create dummy variables to enable each level of 
phase of illness and model of care (categorical variables) 
to be assessed individually. Internal validation will be 
conducted by using such methods as bootstrapping or 
cross-validation to quantify any optimism in the predic-
tive performance (calibration and discrimination) of the 
developed classification.
Model specification
The casemix classification for each outcome across 
three settings will be presented including all regression 
coefficients and model intercept (figure 2). How to 
use the classification will be explained. Understanding 
how casemix variables predict cost of the episode of 
care enables a robust casemix classification to be devel-
oped. But in order for casemix adjustment to occur, 
there also needs to be a good understanding of how 
the casemix variables impact on clinical outcomes, as 
well as resource use. This casemix adjustment meth-
odology is described in the recently published Depart-
ment of Health document,52 which recommends that 
significant casemix variables are identified, and that 
the size of their relationship with clinical outcomes is 
determined in advance.
Figure 2 Casemix classification specification.
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Multilevel modelling will be undertaken to ensure 
that both of these steps will be delivered in this study by 
determining (1) which casemix criteria are most strongly 
associated with clinical outcomes, allowing for clustering 
at the level of ‘participant’ (where episodes occur in the 
same individual), at the level of ‘model of care’ (where 
care is received according to similar models), and at the 
level of ‘site’ (where care is delivered in a similar way 
within site), and (2) which casemix criteria are the stron-
gest cost predictor (including per diem cost, per phase 
cost and total episode cost).
Model performance
The performance of the casemix classification will 
be assessed in both the development and validation 
data sets. Classification measures including sensitivity, 
specificity, predictive values and net reclassification 
improvement will be reported and cut points selected 
a priori. We will primarily focus on discrimination 
for the classification development phase, and assess 
both discrimination and calibration for the valida-
tion phase.53 Discrimination of the classification will 
be measured using the concordance statistic and CIs 
(c-statistic).54 Calibration of the classification will be 
measured using calibration plot and Hosmer-Leme-
show goodness-of-fit test.55
development versus validation
Data will be collected from patients, caregivers and clini-
cians during the validation phase to compare patient-re-
ported problem severity, that is, ‘felt’ need collected in 
validation phase only (as measured by the patient-re-
ported IPOS) and professional-reported problem severity, 
that is, ‘normative’ need (as measured by the clinician-re-
ported IPOS, phase of illness, AKPS), by reporting 
correlation across levels of complexity and across condi-
tions. We will assess how professional-reported measures 
relate to patient-reported outcomes across different levels 
of complexity (ie, in relation to casemix classes), in order 
to determine optimal outcome measures and quality 
indicators.
We will compare data on resource use from two sources: 
(1) clinician-completed brief PRUS, and (2) patients and 
family-completed CSRI, to better understand how the 
PRUS maps to patients’ receipt of resources, and evaluate 
which generic services are used across different providers, 
regions and the context of different models of specialist 
palliative care.
Ethical considerations
The study protocol and documents (eg, the partici-
pant information sheet, consent and declaration form) 
have been approved by the NHS Health Research 
Authority London—Camberwell St Giles Research Ethics 
committee (15/LO/0887) for the development phase, 
and NHS Health Research Authority London—Bromley 
Research Ethics committee (16/LO/1021) for the valida-
tion phase.
All eligible participants are fully informed before 
consent is sought by the local research team or 
research nurses or project research team through the 
information sheets and verbal explanation on the aims 
and methods of the study and procedures that might 
be involved. Participants can withdraw at any time up 
to analysis of their data, without giving any reason. It 
is possible that participants may become distressed or 
raise issues during this study which raise concerns or 
warrant a change in their medical management, but 
we do not expect the questionnaires will themselves 
cause distress so much as uncover pre-existing distress 
which has not been acknowledged or recognised. 
Should this be the case, then our distress protocol will 
be followed. We anticipate distress will be infrequent, 
given the general nature of the questionnaires. It is 
likely that any distress will reflect advanced disease and 
experiences of care, and not the questionnaires them-
selves. All of the study team members have completed 
Good Clinical Practice training, and specific training 
on addressing distress in palliative care.
Our existing Patient/Public Advisory Group and 
extended Consumer Panel have been and will continue 
to be consulted throughout the study to ensure that the 
study is carried out in an ethical and respectful way, and 
has the highest possible relevance and benefit to patients 
and families. A Project Steering Committee meets once 
every six months to monitor recruitment, review the 
detailed progress of the study and make recommenda-
tions for overall direction and strategy.
dissemination
This study will lead to patient benefit through improved 
matching of resources to needs at individual patient-level 
and will better enable the NHS to deliver high-quality, 
patient-centred palliative care in last year of life. The 
results of the study will be published in peer-reviewed 
publications and will also be presented at national and 
international conferences.
Author affiliations
1Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, 
King's College London, London, UK
2Department of Primary Care and Public Health Sciences, King's College London, 
London, UK
3University of Wollongong, Australian Health Services Research Institute, Centre for 
Health Service Development, Wollongong, Australia
4Wolfson Palliative Care Research Centre, Hull York Medical School, University of 
Hull, Hull, UK
Acknowledgements This article presents independent research C-CHANGE 
funded by the National Institute for Health Research (NIHR) under the Programme 
Grants for Applied Research scheme (RP-PG-1210-12015) and the NIHR CLAHRC 
funding scheme, through the Collaboration for Leadership in Applied Health 
Research and Care South London (NIHR CLAHRC South London) at King's College 
Hospital NHS Foundation Trust. The C-CHANGE research team acknowledges the 
support of the National Institute of Health Research Clinical Research Network 
(NIHR CRN). 
Contributors PG drafted the study protocol with input from all authors. MD, 
JMD and AD provided statistical advice and support. AMF, SMO, CP, SP and PG 
contributed to the acquisition and interpretation of data for the work. IJH and 
 o
n
 25 April 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020071 on 17 March 2018. Downloaded from 
9Guo P, et al. BMJ Open 2018;8:e020071. doi:10.1136/bmjopen-2017-020071
Open Access
FEMM conceived the study and were in charge of overall direction and planning. 
KE provided experience from the Australian palliative care casemix development. 
FEMM is the chief investigator and designed the C-CHANGE research programme 
of which this is part. All authors provided critical feedback, helped revise the 
manuscript and are accountable for the accuracy and integrity of all aspects of the 
work.
Funding This work was supported by NIHR Programme Grants for Applied 
Research (grant number RP-PG-1210-12015). 
disclaimer The views expressed in this article are those of the author(s) and not 
necessarily those of the National Health Service, the National Institute for Health 
Research, or the Department of Health and Social Care.
Competing interests None declared.
Patient consent Detail has been removed from this case description/these case 
descriptions to ensure anonymity. The editors and reviewers have seen the detailed 
information available and are satisfied that the information backs up the case the 
authors are making. 
Ethics approval The NHS Health Research Authority (HRA) Approval. 
Provenance and peer review Not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits 
others to distribute, remix, adapt and build upon this work, for commercial use, 
provided the original work is properly cited. See: http:// creativecommons. org/ 
licenses/ by/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
rEFErEnCEs
 1. Currow DC, Abernethy AP, Fazekas BS. Specialist palliative care 
needs of whole populations: a feasibility study using a novel 
approach. Palliat Med 2004;18:239–47.
 2. Fitch MI. Needs of patients living with advanced disease. Can Oncol 
Nurs J 2005;15:230–5.
 3. Department of Health. Assessing health care needs. London: 
National Health Service Management Executive, 1991.
 4. The Economist Intelligence Unit. The 2015 Quality of Death Index: 
Ranking palliaitve care across the world. 2015.
 5. Sleeman KE, Davies JM, Verne J, et al. The changing demographics 
of inpatient hospice death: Population-based cross-sectional study 
in England, 1993-2012. Palliat Med 2016;30:45–53.
 6. Rosenwax L, Spilsbury K, McNamara BA, et al. A retrospective 
population based cohort study of access to specialist palliative care 
in the last year of life: who is still missing out a decade on? BMC 
Palliat Care 2016;15:46.
 7. Hughes-Hallett T, Craft A, Davies C, et al. Funding the right care and 
support for everyone: creating a fair and transparent funding system. 
J Pain Palliat Care Pharmacother 2011;25:362–4.
 8. Lancaster H, Finlay I, Downman M, et al. Commissioning of specialist 
palliative care services in England. BMJ Support Palliat Care 2018;8.
 9. Etkind SN, Bone AE, Gomes B, et al. How many people will 
need palliative care in 2040? Past trends, future projections and 
implications for services. BMC Med 2017;15:102.
 10. Lee LA, Eagar KM, Smith MC. Subacute and non-acute casemix in 
Australia. Med J Aust 1998;169(Suppl):22–5.
 11. Eagar K, Cromwell D, Kennedy C, et al. Classifying sub-acute and 
non-acute patients: results of the New South Wales Casemix Area 
Network study. Aust Health Rev 1997;20:26–42.
 12. Turner-Stokes L, Sutch S, Dredge R, et al. International casemix 
and funding models: lessons for rehabilitation. Clin Rehabil 
2012;26:195–208.
 13. Eagar K, Gordon R, Hodkinson A, et al. The Australian National 
Sub-Acute and Non-Acute Patient Classification (AN-SNAP): report 
of the national sub-acute and non-acute casemix classification study. 
Wollongong: Centre for Health Service Development, University of 
Wollongong, 1997.
 14. Eagar K, Green J, Gordon R. An Australian casemix classification 
for palliative care: technical development and results. Palliat Med 
2004;18:217–26.
 15. Eagar K, Watters P, Currow DC, et al. The Australian Palliative 
Care Outcomes Collaboration (PCOC)–measuring the quality and 
outcomes of palliative care on a routine basis. Aust Health Rev 
2010;34:186–92.
 16. Eagar K, Gordon R, Green J, et al. An Australian casemix 
classification for palliative care: lessons and policy implications of a 
national study. Palliat Med 2004;18:227–33.
 17. Collins GS, Reitsma JB, Altman DG, et al. Transparent Reporting of a 
multivariable prediction model for Individual Prognosis or Diagnosis 
(TRIPOD): the TRIPOD statement. Ann Intern Med 2015;162:55–63.
 18. Hinds J. National survey of patient activity data for specialist palliative 
care services: Minimum Data Set (MDS) full report for the year 2014-
2015. London: The National Council for Palliative Care, 2016.
 19. Castro FG, Kellison JG, Boyd SJ, et al. A methodology for 
conducting integrative mixed methods research and data analyses. J 
Mix Methods Res 2010;4:342–60.
 20. Hjermstad M, Loge JH, Kaasa S. Methods for assessment of 
cognitive failure and delirium in palliative care patients: implications 
for practice and research. Palliat Med 2004;18:494–506.
 21. Radbruch L, Sabatowski R, Loick G, et al. Cognitive impairment and 
its influence on pain and symptom assessment in a palliative care 
unit: development of a Minimal Documentation System. Palliat Med 
2000;14:266–76.
 22. Higginson IJ, McCrone P, Hart SR, et al. Is short-term palliative care 
cost-effective in multiple sclerosis? A randomized phase II trial. J 
Pain Symptom Manage 2009;38:816–26.
 23. Bausewein C, Booth S, Gysels M, et al. Individual breathlessness 
trajectories do not match summary trajectories in advanced 
cancer and chronic obstructive pulmonary disease: results from a 
longitudinal study. Palliat Med 2010;24:777–86.
 24. Buller T. Advance consent, critical interests and dementia research. J 
Med Ethics 2015;41:701–7.
 25. Mather H, Guo P, Firth A, et al. Phase of Illness in palliative care: 
Cross-sectional analysis of clinical data from community, hospital 
and hospice patients. Palliat Med 2018;32:404–12.
 26. Masso M, Allingham SF, Banfield M, et al. Palliative care phase: 
inter-rater reliability and acceptability in a national study. Palliat Med 
2015;29:22–30.
 27. Coventry PA, Grande GE, Richards DA, et al. Prediction of 
appropriate timing of palliative care for older adults with non-
malignant life-threatening disease: a systematic review. Age Ageing 
2005;34:218–27.
 28. Franks PJ, Salisbury C, Bosanquet N, et al. The level of need for 
palliative care: a systematic review of the literature. Palliat Med 
2000;14:93–104.
 29. Luddington L, Cox S, Higginson I, et al. The need for palliative care 
for patients with non-cancer diseases: a review of the evidence. Int J 
Palliat Nurs 2001;7:221–6.
 30. Tebbit P. Population-based needs assessment for palliaitve and end 
of life care. London: National Council for Palliative Care, 2008.
 31. Drummond M, Weatherly H, Ferguson B. Economic evaluation of 
health interventions. BMJ 2008;337:a1204.
 32. Kirch W. Encyclopedia of public health. Dordrecht: Springer 
Netherlands, 2008.
 33. Curtis L. Unit costs of health and social care. Canterbury: Personal 
Social Services Research Unit, University of Kent, 2014.
 34. Joint Formulary Committe. British National Formulary (BNF) 68. 
London: BMJ Publishing Group Ltd and Royal Pharmaceutical 
Society, 2014.
 35. Department of Health. NHS reference costs 2013 to 2014. 2014.
 36. Wolff J, McCrone P, Patel A, et al. A time study of physicians work in 
a German university eye hospital to estimate unit costs. PLoS One 
2015;10:e0121910.
 37. Sutherland JM. Pricing hospital care: global budgets and marginal 
pricing strategies. Health Policy. In Press. 2015;119:1111–8.
 38. Tan SS, Bakker J, Hoogendoorn ME, et al. Direct cost analysis 
of intensive care unit stay in four European countries: applying a 
standardized costing methodology. Value Health 2012;15:81–6.
 39. Department of Health. NHS costing manual. 2012.
 40. Abernethy AP, Shelby-James T, Fazekas BS, et al. The Australia-
modified Karnofsky Performance Status (AKPS) scale: a 
revised scale for contemporary palliative care clinical practice 
[ISRCTN81117481]. BMC Palliat Care 2005;4:7.
 41. Collin C, Wade DT, Davies S, et al. The barthel ADL Index: a reliability 
study. Int Disabil Stud 1988;10:61–3.
 42. King J, Gibbons E, Graham C, et al.  Developing measures of 
people's self-reported experiences of integrated care. Geneva: Picker 
Institute Europe and University of Oxford, 2013.
 43. Koffman J, Higginson IJ, Hall S, et al. Bereaved relatives views about 
participating in cancer research. Palliat Med 2012;26:379–83.
 44. Addington-Hall J, McPherson C. After-death interviews with 
surrogates/bereaved family members: some issues of validity. J Pain 
Symptom Manage 2001;22:784–90.
 45. Costantini M, Beccaro M, Merlo F. The last three months of life 
of Italian cancer patients. Methods, sample characteristics and 
 o
n
 25 April 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020071 on 17 March 2018. Downloaded from 
10 Guo P, et al. BMJ Open 2018;8:e020071. doi:10.1136/bmjopen-2017-020071
Open Access 
response rate of the Italian Survey of the Dying of Cancer (ISDOC). 
Palliat Med 2005;19:628–38.
 46. Wilson Van Voorhis CR, Morgan BL. Understanding power and rules 
of thumb for determining sample sizes. Tutor Quant Methods Psychol 
2007;3:43–50.
 47. Ogundimu EO, Altman DG, Collins GS. Adequate sample size for 
developing prediction models is not simply related to events per 
variable. J Clin Epidemiol 2016;76:175–82.
 48. Currow DC, Allingham S, Yates P, et al. Improving national 
hospice/palliative care service symptom outcomes systematically 
through point-of-care data collection, structured feedback and 
benchmarking. Support Care Cancer 2015;23:307–15.
 49. Gao J, Johnston GM, Lavergne MR, et al. Identifying population 
groups with low palliative care program enrolment using 
classification and regression tree analysis. J Palliat Care 
2011;27:98–106.
 50. Lemon SC, Roy J, Clark MA, et al. Classification and regression tree 
analysis in public health: methodological review and comparison with 
logistic regression. Ann Behav Med 2003;26:172–81.
 51. Pinnock H, Kendall M, Murray SA, et al. Living and dying with 
severe chronic obstructive pulmonary disease: multi-perspective 
longitudinal qualitative study. BMJ 2011;342:d142.
 52. Department of Health. Patient reported outcome measures (PROMs) 
in England: the case-mix adjustment methodology. 2012.
 53. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the 
performance of prediction models: a framework for traditional and 
novel measures. Epidemiology 2010;21:128–38.
 54. Cook NR. Statistical evaluation of prognostic versus diagnostic 
models: beyond the ROC curve. Clin Chem 2008;54:17–23.
 55. Austin PC, Steyerberg EW. Graphical assessment of internal and 
external calibration of logistic regression models by using loess 
smoothers. Stat Med 2014;33:517–35.
 o
n
 25 April 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020071 on 17 March 2018. Downloaded from 
